ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACADIA Pharmaceuticals stock.
View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 12,000,000 shares, an increase of 48.0% from the April 15th total of 8,110,000 shares. Based on an average trading volume of 1,570,000 shares, the short-interest ratio is presently 7.6 days. Currently, 7.5% of the company's shares are short sold.
View ACADIA Pharmaceuticals' Short Interest.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for ACADIA Pharmaceuticals.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.27. The biopharmaceutical company had revenue of $115.47 million for the quarter, compared to analysts' expectations of $122.22 million. ACADIA Pharmaceuticals had a negative net margin of 43.50% and a negative trailing twelve-month return on equity of 40.52%. The business's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.42) EPS.
View ACADIA Pharmaceuticals' earnings history.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $510.00 million-$560.00 million, compared to the consensus revenue estimate of $540.68 million.

What price target have analysts set for ACAD?

17 brokers have issued 1 year target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $23.00 to $37.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $29.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:

• Mr. Stephen R. Davis J.D., CEO & Director (Age 61, Pay $1.23M) (LinkedIn Profile)
• Dr. Srdjan R. Stankovic, Pres (Age 65, Pay $1.12M) (LinkedIn Profile)
• Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 58, Pay $626.76k) (LinkedIn Profile)
• Mr. Mark C. Schneyer, Exec. VP & CFO
• Mr. Brendan Teehan, Exec. VP, COO & Head of Commercial (LinkedIn Profile)
• Mr. James K. Kihara, VP, Chief Accounting Officer & Corp. Controller (Age 41) (LinkedIn Profile)
• Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
• Dr. Kathie M. Bishop Ph.D., Sr. VP, Chief Scientific Officer & Head of Rare Disease (Age 56)
• Mr. Mark C. Johnson, VP of Investor Relations
• Ms. Julie Fisher, Sr. VP of Marketing & Commercial Strategy

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Who are some of ACADIA Pharmaceuticals' key competitors?

Some companies that are related to ACADIA Pharmaceuticals include Biohaven Pharmaceutical (BHVN), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Acerus Pharmaceuticals (ASPCF), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND) and Hypera (HYPMY).
View all of ACAD's competitors.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.79%), BlackRock Inc. (6.18%), State Street Corp (3.13%), First Trust Advisors LP (1.44%), JPMorgan Chase & Co. (1.43%) and Palo Alto Investors LP (1.39%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Brendan Teehan, Elena Ridloff, James Kihara, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Federated Hermes Inc., Frontier Capital Management Co. LLC, UBS Group AG, BlackRock Inc., Palo Alto Investors LP, Goldman Sachs Group Inc., and Jane Street Group LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Brendan Teehan, James Kihara, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, Invesco Ltd., Vanguard Group Inc., Sessa Capital IM L.P., State Street Corp, JPMorgan Chase & Co., The Manufacturers Life Insurance Company , and Panagora Asset Management Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $17.11.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $2.76 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167.87 million in net income (profit) each year or ($1.330010) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 514 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872.